| REZOLUTE INC. NEW DL-,001 |
| USA |
| Gesundheit |
| US76200L3096 / A2QEWP |
| 6HV1 (Frankfurt) / RZLT (NASDAQ) |
| FRA:6HV1, ETR:6HV1, 6HV1:GR, NASDAQ:RZLT |
| - |
| https://rezolutebio.com/ |
|
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclon..
>Volltext.. |
| 350.54 Mio. EUR |
| 271.28 Mio. EUR |
| - |
| -74.38 Mio. EUR |
| -70.25 Mio. EUR |
| -0.67 EUR |
| 0.68 Mio. EUR |
| 7.35 Mio. EUR |
| -59.49 Mio. EUR |
| 9.51 |
| - |
| -4.58% |
| - |
| - |
| - |
| - |
| REZOLUTE |
| 13.11.26 |
|